Discovery of Novel sEH Inhibitor Candidates and External Collaborative Research
First written in FY2023-Q3. 7 of 14 entries say "Advanced", first in FY2023. Latest entry: 2026-08-14.
No other company in this theme has enough history to compare yet.
- 2026-08-14First statedPresentation materials for financial results
「Novel oral sEH inhibitor (R-002) Completion of pharmacodynamic and pharmacological studies; evaluation of indications and CMC Conduct of preliminary toxicity and safety studies」
The novel oral sEH inhibitor was presented in the pipeline as R-002, with milestones including pharmacodynamic and pharmacological studies, evaluation of indications and CMC, and preliminary toxicity and safety studies. These were described as planned activities, not completed or conducted results. - FY2027-H1AdvancedAnnual report
「The Company filed patent applications in January 2026 for a group of more than 100 novel compounds obtained through these efforts. It also continued examining expanded indications for TMS-008 and began collaborative research with Kyushu University and Tohoku University.」
The Company advanced pharmacological, efficacy and toxicity evaluations of novel sEH inhibitor candidates, confirming preliminary safety and efficacy in multiple disease animal models. It filed patent applications for more than 100 novel compounds in January 2026 and began collaborative research with Kyushu University and Tohoku University on expanded indications for TMS-008. - FY2026-H1RestatedAnnual report
「The Company obtained promising candidate compounds from these efforts and continued pharmacological, efficacy and toxicity evaluations. It also continued examining additional indications for TMS-008.」
The Company continued evaluating candidates obtained through AI-based compound generation and natural-product library screening, including pharmacological, efficacy and toxicity testing. - FY2025AdvancedAnnual report
「The Company obtained promising candidate compounds from these efforts and proceeded with pharmacological, efficacy and toxicity evaluations.」
Promising candidates identified through AI-based compound generation and natural-product library screening advanced to pharmacological, efficacy and toxicity testing. - FY2025-H1RestatedAnnual report
「The Company obtained promising candidate compounds from these efforts and proceeded with their evaluation. It also continued examining additional indications for TMS-008.」
The Company continued obtaining and evaluating promising candidates and considering additional indications for TMS-008. - FY2025-Q1AdvancedAnnual report
「The Company obtained promising candidate compounds from these efforts and proceeded with their evaluation. It also continued examining additional indications for TMS-008.」
The Company obtained and began evaluating promising candidates identified through AI-based compound generation and natural-product library screening. It also continued considering additional indications for TMS-008. - FY2024-Q3RestatedAnnual report
「In its internal program, the Company used its knowledge and experience in sEH inhibition developed through SMTP compound research and development, applying multiple approaches including AI-based compound generation to optimize drug discovery and screening of natural-product libraries to search for new sEH inhibitor candidates.」
The Company continued searching for novel sEH inhibitor candidates using multiple methods, including AI-based compound generation and natural-product library screening. - FY2024-Q2RestatedAnnual report
「In its internal program, the Company used its knowledge and experience in sEH inhibition developed through SMTP compound research and development, applying multiple approaches including AI-based compound generation to optimize drug discovery and screening of natural-product libraries to search for new sEH inhibitor candidates.」
The Company continued searching for novel sEH inhibitor candidates using multiple methods, including AI-based compound generation and natural-product library screening. - FY2024-Q1RestatedAnnual report
「In its internal program, the Company used its knowledge and experience in sEH inhibition developed through SMTP compound research and development, applying multiple approaches including AI-based compound generation to optimize drug discovery and screening of natural-product libraries to search for new sEH inhibitor candidates.」
The Company continued searching for novel sEH inhibitor candidates using multiple methods, including AI-based compound generation and natural-product library screening. - FY2023AdvancedAnnual report
「The Company used its knowledge and experience in sEH inhibition developed through research and development of the SMTP compounds (TMS-007 and TMS-008), applying multiple approaches including AI-based compound generation to optimize drug discovery and screening of natural-product libraries to search for new sEH inhibitor candidates.」
The Company used multiple discovery methods, including AI-based compound generation and natural-product library screening, to search for novel sEH inhibitor candidates. - FY2023-Q3First statedAnnual report
「For pipeline programs other than the SMTP compounds, the Company is using knowledge gained from its research and development on soluble epoxide hydrolase (sEH) inhibition to search for new compounds that could be sEH inhibitor candidates, and has begun collaborative research with external organizations on sEH inhibition.」
The Company is searching for novel candidate compounds based on its sEH inhibition expertise and has begun collaborative research with external organizations.